摘要
目的探讨表柔比星联合卡培他滨治疗三阴性乳腺癌的疗效、安全性及对患者血清血管内皮生长因子C（vascular endothelial growth factor C,VEGF-C）水平的影响。方法选取2013年1月~2014年12月于贵阳中医学院第一附属医院接受治疗的86例三阴性乳腺癌患者作为研究对象,按照治疗方案分为对照组42例和观察组44例。对照组给予表柔比星治疗,观察组在对照组基础上联合应用卡培他滨治疗。疗程结束后,观察比较2组患者近期疗效、不良反应及血清VEGF-C水平。结果疗效评价后,观察组近期有效率高于对照组,但2组间比较差异无统计学意义。治疗期间,2组患者中性粒细胞减少症、手足综合症、胃肠道反应、心脏损害、肝脏损害等不良反应发生率比较无统计学差异。治疗后,与对照组相比,观察组VEGF-C水平显著下降（P〈0.05）。结论表柔比星联合卡培他滨治疗三阴性乳腺癌效果良好,具有较高的近期有效率,且不增加不良反应发生率,并能明显降低血清VEGF-C水平。
Objective To investigate curative efficacy and safety of Epirubicin in combination with Capecitabine in the treatment of triple-negative breast cancer and its effects on level of serum vascular endothelial growth factor C（ VEGF-C）. Methods 86 patients of triple-negative breast cancer who received therapy from January 2013 to December 2014 were selected as research objects. According to therapeutic schemes,those patients were divided into control group（ n = 42） and observation group（ n = 44）. Control group was treated with epirubicin,while observation group was treated with Epirubicin in combination with Capecitabine. Then,the short-term curative efficacy,adverse events effects,level of VEGF-C were observed and compared. Results After the course of treatment,the short-term curative efficacy ratio in control group and observation group was 59. 5% and 65. 9% respectively with no statistical difference. During the treatment,the occurrence of neutropenia,hand-foot syndrome,gastrointestinal reaction,cardiac damage and liver function damage in the two groups was statistically same respectively. After post-treatment,in comparison with control group,level of VEGF-C in observation group was statistically lower（ P〈0. 05）. Conclusion Epirubicin in combination with Capecitabine is effective for triple-negative breast cancer,which has high short-term curative efficacy ratio and significantly decrease level of VEGF-C with not increasing occurrence of toxic side effects.
出处
《中国生化药物杂志》
CAS
2015年第9期138-140,共3页
Chinese Journal of Biochemical Pharmaceutics
基金
国家自然科学基金项目(81460697)
贵州省研究生工作站计划(黔教研合JYSZ字[2014]018)
贵州省科技支撑计划社会发展攻关项目(黔科合SY字[2014]3026号)
关键词
表柔比星
卡培他滨
三阴性乳腺癌
血管内皮生长因子C
Epirubicin
Capecitabine
triple-negative breast cancer
vascular endothelial growth factor C
作者简介
罗莉，女，硕士。副主任医师，研究方向：妇科肿瘤的临床治疗及基础研究，E-mail：lir197508@163．com；
唐东昕，通讯作者，男，博士，教授，硕士研究生导师．研究方向：中医药防治肿瘤的基础及临床研究．E-mail：tangdongxin@sina．com.
